| Project/Area Number |
20590910
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
OHSAKI Yoshinobu Asahikawa Medical College, 医学部, 教授 (30191935)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
川辺 淳一 旭川医科大学, 医学部, 特任准教授 (10400087)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Keywords | EPCs / PGI2-IP signaling / 肺癌 / 癌転移 / 治療 / 血管新生 / 骨髄由来血管内皮前駆細胞 / 肺転移 / プロスタサイクリン / 骨髄細胞 / ドラックデリバリーシステム / 転移癌 / 腫瘍血管 |
|---|
| Research Abstract |
PGI2-IP signaling in EPCs is crucial for neovascularization, and plays an important role for tumor growth. PGI2-IP signaling in bone marrow-derived cells (BMDCs), including EPCs, participates in the process of the formation of lung tumor metastasis in lung very much. We showed the possibility of lung cancer treatment targeting PGI2-IP signaling.
|
